Senti Bio Announces First Quarter 2024 Results and Reviews Recent Corporate Highlights
09 mai 2024 16h05 HE
|
Senti Biosciences, Inc.
Senti Biosciences, Inc. (Nasdaq: SNTI) today reported operational updates and financial results for the first quarter of 2024.
Bellicum Receives FDA IND Clearance to Initiate a Phase 1/2 Clinical Trial for BPX-603, a Dual-Switch GoCAR-T® for HER2+ Solid Tumors
15 juin 2020 07h30 HE
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, June 15, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced clearance by...
Bellicum Pharmaceuticals Licenses Its CaspaCIDe® Safety Switch to MD Anderson
11 déc. 2019 07h30 HE
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Dec. 11, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that The...